Loading...
•
Jun 30, 2021
Boston Scientific Q2 2021 Earnings Report
Boston Scientific's Q2 2021 earnings were announced, revealing substantial revenue growth and exceeding guidance.
Key Takeaways
Boston Scientific reported strong second-quarter results with net sales of $3.077 billion, a 53.6% increase year-over-year. GAAP EPS was $0.12, and adjusted EPS was $0.40, exceeding guidance. The company experienced faster-than-market growth in most segments.
Net sales increased by 53.6% on a reported basis, exceeding the company's guidance range.
GAAP net income per share was $0.12, while adjusted EPS reached $0.40, surpassing the guidance range.
All reportable segments achieved net sales growth compared to the prior year period.
The company completed the European CE Mark for the EXALT™ Model B Single-Use Bronchoscope.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Revenue by Segment
MedSurg Revenue
CapyFin.comCardiovascular Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope, Middle East & Africa Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.comEmerging Markets Revenue
CapyFin.com Forward Guidance
The company estimates net sales growth for the full year 2021 to be in the range of approximately 21 to 22 percent on a reported basis, and approximately 19 to 20 percent on an organic basis. The company estimates net sales growth for the third quarter of 2021 to be in a range of approximately 12 to 14 percent on both a reported and organic basis.
Positive Outlook
- Full year 2021 reported net sales growth estimated between 21% and 22%.
- Full year 2021 organic net sales growth estimated between 19% and 20%.
- Full year 2021 GAAP EPS estimated between $0.79 and $0.83.
- Full year 2021 adjusted EPS estimated between $1.58 and $1.62.
- Third quarter 2021 net sales growth estimated between 12% and 14% on both a reported and organic basis.
Challenges Ahead
- Guidance excludes the impact of foreign currency fluctuations.
- Guidance excludes the impact of the Preventice Solutions, Inc. acquisition in Q1 2021.
- Guidance excludes the intrauterine health franchise divestiture in Q2 2020.
- Guidance excludes the Specialty Pharmaceuticals business divestiture in Q1 2021.
- Future economic, political, competitive, reimbursement and regulatory conditions could affect results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income